STOCK TITAN

ICON Secures Upgraded Credit Rating from S&P Global Ratings

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
ICON plc (NASDAQ: ICLR) upgraded to investment grade credit rating of BBB- by S&P Global Ratings.
Positive
  • ICON's operating performance and deleveraging led to the upgrade in credit rating.
  • Expansion of scope with existing clients and cost management contributed to profitability.
  • The upgrade reflects the strong financial position of the company.
Negative
  • None.

DUBLIN--(BUSINESS WIRE)-- ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that S&P Global Ratings (S&P) upgraded ICON to an investment grade credit rating of BBB- with a stable outlook, based on operating performance and deleveraging.

S&P upgraded ICON from a ‘BB+’ rating to a ‘BBB-’, raising their long-term issuer credit rating and their issue rating on the group’s senior secured term debt.

S&P highlighted in their report, “ICON’s solid operating performance and voluntary debt prepayments improve credit metrics to a level commensurate with an investment-grade rating”. S&P also cite the expansion of scope with existing clients, and profitability benefitting from realized cost synergies relating to the successful integration of PRA Health Sciences together with continued disciplined cost management by ICON as additional rationale to support their upgrade.

Brendan Brennan, Chief Financial Officer, commented: “We are proud of the investment grade rating upgrade from S&P, which is aligned with our stated long-term capital allocation priorities for ICON, and indicative of the strong financial position of the company. Achieving this milestone reflects continued focus on strong cost management and the realization of the operational benefits following the successful integration of PRA Health Sciences”.

About ICON plc

ICON plc is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,160 employees in 108 locations in 53 countries as at June 30, 2023. For further information about ICON, visit: www.iconplc.com.

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, the impact of COVID-19 on our business, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at http://www.sec.gov.

Source: ICON plc

ICON/ICLR-F

Kate Haven Vice President Investor Relations +1888 381 7923

Source: ICON plc

FAQ

What is the new credit rating of ICON?

ICON has been upgraded to an investment grade credit rating of BBB-.

What factors led to the upgrade in credit rating?

ICON's operating performance, deleveraging, expansion of scope with existing clients, and cost management contributed to the upgrade.

Who upgraded ICON's credit rating?

S&P Global Ratings upgraded ICON's credit rating.

What does the upgrade reflect?

The upgrade reflects the strong financial position of ICON.

What is the stock symbol for ICON?

ICON's stock symbol is ICLR.

ICON Public Limited Company

NASDAQ:ICLR

ICLR Rankings

ICLR Latest News

ICLR Stock Data

26.52B
81.31M
0.66%
101.49%
1.68%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Dublin 18

About ICLR

icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. we specialise in the strategic development, management and analysis of programmes that support clinical development - from compound selection to phase i-iv clinical studies. in a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis. we have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. we are also an 'end-to-end'​ pharmacovigilance service provider and this includes post marketing surveillance activities too.